CD247 and acute myeloid leukemia: From April 2015 to July 2016, a phase I (ClinicalTrials.gov number, NCT02203825) dose-escalation study was performed to establish the feasibility and safety of NKG2D-DAP10-CD3ζ CAR T cells (CM-CS1 T cells) in treating AML and was completed ahead of schedule.